Summit Therapeutics PLC(SMMT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SMMT Summit Therapeutics PLC

Trading 04-27 14:40:05 EDT

22.26

+0.18

+0.79%

High22.55	Low21.81	Vol2.57M
Open22.08	D1 Closing22.08	Amplitude3.35%
Mkt Cap17.26B	Tradable Cap2.87B	Total Shares775.37M
T/O57.52M	T/O Rate2.00%	Tradable Shares129.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SMMT","market":"US","secType":"STK","nameCN":"Summit Therapeutics PLC","latestPrice":22.255,"timestamp":1777315204024,"preClose":22.08,"halted":0,"volume":2574830,"delay":0,"changeRate":0.007925724637681193,"floatShares":129000000,"shares":775372700,"eps":-1.44,"marketStatus":"Trading","change":0.175,"latestTime":"04-27 14:40:05 EDT","open":22.08,"high":22.55,"low":21.81,"amount":57520705.74079,"amplitude":0.033514,"askPrice":22.26,"askSize":214,"bidPrice":22.25,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.44,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1777320000000},"marketStatusCode":2,"adr":1,"adrRate":5,"listingDate":1425531600000,"exchange":"NASDAQ","adjPreClose":22.08,"preHourTrading":{"tag":"盘前","latestPrice":22.12,"preClose":22.08,"latestTime":"09:28 EDT","volume":7840,"amount":176047.03536,"timestamp":1777296481063,"change":0.04,"changeRate":0.001812,"amplitude":0.025362},"postHourTrading":{"tag":"盘后","latestPrice":22.1,"preClose":22.08,"latestTime":"19:56 EDT","volume":40705,"amount":898369.641,"timestamp":1777074961537,"change":0.02,"changeRate":0.000906,"amplitude":0.015702},"volumeRatio":0.503965,"impliedVol":1.3001,"impliedVolPercentile":0.9801},"requestUrl":"/m/hq/s/SMMT","defaultTab":"news","newsList":[{"id":"1153470505","title":"Electric Vehicle Adoption Reaches 'Tipping Point' Globally, Trend Deemed Self-Sustaining","url":"https://stock-news.laohu8.com/highlight/detail?id=1153470505","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153470505?lang=en_us&edition=fundamental","pubTime":"2026-04-26 14:38","pubTimestamp":1777185528,"startTime":"0","endTime":"0","summary":"Multiple studies and market data indicate that electric vehicle (EV) adoption has crossed a \"tipping point\" in China, parts of Southeast Asia, and Europe, a trend described by experts as...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HOmain","SMMT","BK4588","BK4139","IE0034235071.USD","LU1863844665.USD","BK4534","LU2488822045.USD","BK4585","LU1863844749.USD","BK4118","LU1829250122.USD","LU3187612489.SGD","UBS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629038853","title":"Summit Therapeutics put volume heavy and directionally bearish","url":"https://stock-news.laohu8.com/highlight/detail?id=2629038853","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629038853?lang=en_us&edition=fundamental","pubTime":"2026-04-23 22:55","pubTimestamp":1776956117,"startTime":"0","endTime":"0","summary":"Bearish flow noted in Summit Therapeutics (SMMT) with 5,713 puts trading, or 14x expected. Most active are Jul-26 20 puts and Jun-26 23 puts, with ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/summit-therapeutics-put-volume-heavy-and-directionally-bearish-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/summit-therapeutics-put-volume-heavy-and-directionally-bearish-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SMMT","BK4139","BK4211","BK4007","LU2488822045.USD","BK4539","LENZ","SMMF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629059223","title":"Summit partner selection for ASCO plenary signals strong OS, says Leerink","url":"https://stock-news.laohu8.com/highlight/detail?id=2629059223","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629059223?lang=en_us&edition=fundamental","pubTime":"2026-04-22 01:15","pubTimestamp":1776791744,"startTime":"0","endTime":"0","summary":"Leerink analyst Daina Graybosch notes that HARMONi-06 overall survival analysis from Akeso and partner Summit Therapeutics (SMMT) was selected as o...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/summit-partner-selection-for-asco-plenary-signals-strong-os-says-leerink-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/summit-partner-selection-for-asco-plenary-signals-strong-os-says-leerink-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2488822045.USD","SMMT","SMMF","BK4139","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629056926","title":"Summit partner selection for ASCO ‘likely a major positive,’ says Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2629056926","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629056926?lang=en_us&edition=fundamental","pubTime":"2026-04-22 00:09","pubTimestamp":1776787744,"startTime":"0","endTime":"0","summary":"Guggenheim contends that investors “should be positively surprised” to see Summit Therapeutics (SMMT)’ partner Akeso’s first disclosure for HARMONi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/summit-partner-selection-for-asco-likely-a-major-positive-says-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/summit-partner-selection-for-asco-likely-a-major-positive-says-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SMMF","LU2488822045.USD","SMMT","BK4139","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628076730","title":"IonQ, Oklo, And Robinhood Are Among the Top 10 Large-Cap Gainers Last Week (April 13-April 17): Are the Others in Your Portfolio?","url":"https://stock-news.laohu8.com/highlight/detail?id=2628076730","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628076730?lang=en_us&edition=fundamental","pubTime":"2026-04-19 22:01","pubTimestamp":1776607260,"startTime":"0","endTime":"0","summary":"Large-cap stocks surged last week as catalysts from short squeezes to innovation-driven momentum fueled broad gains.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/04/19/Robinhood-Robinhood-Mobile-Icon-App-On-A.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/04/19/Robinhood-Robinhood-Mobile-Icon-App-On-A.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/equities/26/04/51903501/ionq-oklo-and-robinhood-are-among-the-top-10-large-cap-gainers-last-week-april-13-april-17-are-the-others-in-your-portfolio","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/equities/26/04/51903501/ionq-oklo-and-robinhood-are-among-the-top-10-large-cap-gainers-last-week-april-13-april-17-are-the-others-in-your-portfolio","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4539","IE0009354923.USD","LU1861215975.USD","BK4227","MSTR","MTYY","QQQJ","BK4585","MSTU","HOOY","BK4106","AFRU","BK4535","ONEQ","MSTP","09399","LU2360107168.USD","IONX","LU1861558580.USD","HOYY","IONL","HOII","APED","MSTX","HOOW","HOOZ","BK4548","MNQmain","QYLG","QID","HOOD","NDX","JEPQ","IYW","NQmain","HOOX","SQQQ","IMST","LMI3.UK","LU0719512351.SGD","MSTY","MSDD","BK4516","HOOG","BK4600","BK4170","BK4602","QDTE","MSTY.UK","PSQ","BK4127","09799","MSII","MSOO","CRDO","BK4596","LU2290526834.HKD","SMST","HOOI","BK4588","BK4141","QLD","WNTR","QQQ","QQQA","IONZ","MSTZ","LU1861559042.SGD","TQQY","LU0082616367.USD","SMMT","NVIW.SI","LU2488822045.USD","ROBN","LU0053671581.USD","HODU","IOYY","BK4023","FTEC","TQQQ","3LMI.UK","3SMI.UK","MST","GPIQ","QQQY","CRDU","BK4139","QQQE","MSTW","MSST","LU1861220033.SGD","07399","BK4591","QQQM","SMI3.UK","07799","BK4595","AFRM","MSTK","BK4547"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628209894","title":"Evercore ISI Reaffirms Their Buy Rating on Summit Therapeutics (SMMT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2628209894","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628209894?lang=en_us&edition=fundamental","pubTime":"2026-04-17 20:41","pubTimestamp":1776429697,"startTime":"0","endTime":"0","summary":"Evercore ISI analyst Cory Kasimov maintained a Buy rating on Summit Therapeutics today and set a price target of $34.00. According to TipRanks, Kas...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/evercore-isi-reaffirms-their-buy-rating-on-summit-therapeutics-smmt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/evercore-isi-reaffirms-their-buy-rating-on-summit-therapeutics-smmt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SMMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628245497","title":"Summit Therapeutics Inc Stock (SMMT) Moved Up by 12.03% on Apr 16: Drivers Behind the Movement","url":"https://stock-news.laohu8.com/highlight/detail?id=2628245497","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628245497?lang=en_us&edition=fundamental","pubTime":"2026-04-17 03:15","pubTimestamp":1776366932,"startTime":"0","endTime":"0","summary":"• Analyst ratings and price targets suggest significant upside potential.\n• FDA accepted BLA for ivonescimab, with a PDUFA date in November 2026.\n• Institutional investors increased holdings, indicating growing conviction.","market":"other","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/market-movers/261791728-market-movers-smmt-20260416","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1069347547.HKD","LU2237443382.USD","LU0096364046.USD","LU1221951129.SGD","LU0203347892.USD","LU1699723380.USD","IE0034235303.USD","LU0672654240.SGD","LU1988902786.USD","LU0238689110.USD","LU1732800096.USD","LU2756315318.SGD","LU0079474960.USD","LU1720051017.SGD","SG9999002224.SGD","SG9999002232.USD","LU0256863902.USD","LU2552382058.USD","SG9999018857.SGD","IE00BJJMRY28.SGD","ELIS","LLII","LU2237443895.HKD","LU1059921491.USD","LU2360032135.SGD","LU2168563687.JPY","LU0208291251.USD","LU0006306889.USD","LU1804176565.USD","LU0882574139.USD","LU0708995401.HKD","IE0002141913.USD","IE00BJJMRZ35.SGD","IE00BN8TJ469.HKD","LU2592432038.USD","LU0320765489.SGD","IE0004445239.USD","LU0158827948.USD","LU1868837300.USD","BK4504","LU2602419157.SGD","LU0965509010.AUD","LU0203201768.USD","LU1280957306.USD","IE0000B7K699.USD","LU2471134879.HKD","LU0868494617.USD","LU0256863811.USD","LU1629891620.HKD","IE00BJT1NW94.SGD","IE00BKDWB100.SGD","LU1934455194.USD","LU1066053197.SGD","SGXZ99366536.SGD","LU1571399168.USD","LU0354030438.USD","LU1585245621.USD","LU2168564065.EUR","LU2417539215.USD","LU1074936037.SGD","BK4533","LU2491050154.USD","LU1366192091.USD","LU2357305700.SGD","LU2112291526.USD","SG9999013999.USD","LU1116320737.USD","LU0417517546.SGD","LU0820561909.HKD","LU1201861249.SGD","SG9999001176.USD","LU1232071149.USD","LU2357627491.SGD","LU0234572021.USD","IE000SO60NU8.SGD","LU0868494708.USD","IE0002270589.USD","LU1941712264.USD","SG9999014567.USD","LU0345770308.USD","LU0786609619.USD","LU2106854487.HKD","LU0234570918.USD","LU1989771016.USD","IE00BZ1G4Q59.USD","IE00B1XK9C88.USD","LU0109391861.USD","SG9999014542.SGD","LU2462157665.USD","IE0001KFT4U8.USD","LU2552382215.SGD","LU2129689431.USD","LU1267930730.SGD","SGXZ51526630.SGD","LU2430703178.SGD","LU1496350502.SGD","IE00B7KXQ091.USD","LU0094547139.USD","LU0203202063.USD","LU2430703095.HKD","LU0640476718.USD","BK4592","BK4534","LU2505996509.AUD","LU2168564495.EUR","SG9999014559.SGD","IE00BFXG1179.USD","LU0225283273.USD","IE00BVYPNV92.GBP","LU1941712348.USD","LU1989772923.USD","SG9999015341.SGD","SG9999014898.SGD","LU0471298777.SGD","LU0345769128.USD","LU0820562030.AUD","LU1127390331.HKD","BK4550","LU0823434740.USD","LU0943347566.SGD","LU1718418525.SGD","SG9999015978.USD","BK4559","LU1894683264.USD","LU1093756325.SGD","SG9999014880.SGD","IE00B3PB1722.GBP","LU2213496289.HKD","LU0965508806.USD","IE000M9KFDE8.USD","LU2746668974.SGD","LU2236285917.USD","LU0323591593.USD","LU2211815571.USD","LU0466842654.USD","IE00B4JS1V06.HKD","LU1814569148.SGD","LU1069344957.HKD","LU2456880835.USD","LU0683600562.USD","LU1720051108.HKD","LU1712237335.SGD","LU1868836591.USD","LU1291159041.SGD","LU1244550577.SGD","SG9999014914.USD","LU1032466523.USD","LU0648001328.SGD","LU1035773651.USD","IE00BFSS8Q28.SGD","BK4581","LU1244550494.USD","LU2347655156.SGD","LU1057294990.SGD","LU2430703251.USD","LU2491049909.HKD","LU0432979614.USD","LU1032955483.USD","LU0130517989.USD","SG9999015358.SGD","IE00BDGV0183.EUR","LU0994945656.USD","LU0795875086.SGD","LU0426412945.USD","LU0426417589.USD","LU1221951046.USD","LU2087625088.SGD","LU2471134523.USD","LU1145028129.USD","LU2023251221.USD","LU2028103732.USD","LU1506573853.SGD","LU0265550359.USD","SG9999014575.USD","LU2756315664.SGD","LU1894683348.USD","LU2750360997.AUD","GB00BDT5M118.USD","LU0097036916.USD","SGXZ31699556.SGD","IE00BKPKM429.USD","LU1244550221.USD","LU0058720904.USD","IE0009355771.USD","SG9999018865.SGD","IE00BK4W5L77.USD","LU1261432733.SGD","LU0965509101.SGD","SG9999001440.SGD","LU1868836914.USD","LU2111349929.HKD","BK4007","IE00B4R5TH58.HKD","SG9999015952.SGD","LU0882574055.USD","LU1093756168.USD","LU1551013425.SGD","LU0964807845.USD","LU2461242641.AUD","LU0980610538.SGD","SG9999015945.SGD","LU2360106947.USD","LU0130102774.USD","LU1023059063.AUD","LU1934455863.HKD","LLYX","IE00BFSS7M15.SGD","LU0965509283.SGD","IE00BSNM7G36.USD","LU0689626769.HKD","LU2271345857.HKD","LU0124676726.USD","LU0353189680.USD","LU0823416689.USD","LU1929549753.HKD","IE000BZT7R73.USD","LU0198837287.USD","LU1674673428.USD","LU0289739699.SGD","LU2125154778.USD","LU2264538146.SGD","LU2361044949.HKD","LU1935042991.SGD","LU0320765992.SGD","LU2063271972.USD","LU1778281490.HKD","IE00B2B36J28.USD","LU2896262040.SGD","LU0061475181.USD","LU2237443622.USD","LU1037948541.HKD","IE00BBT3K403.USD","LU0477156953.USD","SG9999017495.SGD","LU1323610961.USD","LU2168564222.USD","LU2552382132.HKD","IE00BN29S564.USD","LU2089984988.USD","LU1162221912.USD","LU2125154935.USD","LU1732799900.SGD","LU0266013472.USD","LU1974910355.USD","LU2488822045.USD","LU2237438978.USD","LU2168564149.EUR","LU2361044865.SGD","LU1548497426.USD","LU0861579265.USD","LU0122379950.USD","LU0456855351.SGD","LU0912757837.SGD","IE00BLSP4239.USD","LU0158827781.USD","LU2237443549.SGD","IE00B19Z3581.USD","IE00BKVL7J92.USD","LU1674673691.USD","BK4599","LU0114720955.EUR","LU0109394709.USD","BK4532","LU1116320901.HKD","LU0823434583.USD","LU0203345920.USD","IE00BJJMRX11.SGD","LU0316494557.USD","LU0942090050.USD","IE00BVYPNW00.USD","LU2023250330.USD","BK4568","LU2133065610.SGD","LU0320765646.SGD","LU2089284900.SGD","LU1989772840.SGD","IE00BGHQF631.EUR","LU1868837136.USD","LU2237443465.HKD","BK4588","IE00BWXC8680.SGD","IE00B3T34201.USD","LU2505996681.GBP","LU1551013342.USD","SG9999001176.SGD","LU0133085943.USD","LU0106261372.USD","IE0005OL40V9.USD","LU2129689605.HKD","LU0889566641.SGD","LU2023250843.SGD","LU1196500208.SGD","IE00B19Z3B42.SGD","IE00BLSP4452.SGD","LU1035775433.USD","IE0004445015.USD","LU0792757196.USD","SGXZ81514606.USD","SG9999015986.USD","LU0070217475.USD","LU2265009873.SGD","IE00B775H168.HKD","LU2361045086.USD","LU2324357040.USD","LU1066051498.USD","LU0889565916.HKD","LU2129689514.USD","LU0210536198.USD","LU2023250504.SGD","IE00BK4W5M84.HKD","BK4139","LU2491050071.SGD","LU1267930813.SGD","LU1061106388.HKD","LU1121112475.USD","LU0353189763.USD","BK4585","IE00BFTCPJ56.SGD","IE000WAW04H5.SGD","LU2471134796.USD","IE00B1BXHZ80.USD","LU2471134952.CNY","LU1066051225.USD","LU0070302665.USD","ELIL","LLYZ","SG9999014906.USD","BK4516","LU2108987350.USD","LU1043141396.HKD","LU2089283258.USD","LU1064131342.USD","LU0345770993.USD","LU0098860793.USD","LU2237443978.SGD","LU1914381329.SGD","LU0859254822.USD","LU0471298694.HKD","IE00B42XCP33.USD","LU1043141123.HKD","LU1066051811.HKD","LU0820561818.USD","LU1917777945.USD","LU0985320562.USD","LU0345769631.USD","LU2468319806.SGD","LU0354030511.USD","LU0787776722.HKD","LU1983299246.USD","LU1037948897.HKD","LU1868836757.USD","LU0385154629.USD","LU2746668461.USD","IE000F7OJYX1.SGD","IE00BJLML261.HKD","LU0320765059.SGD","LU0689472784.USD","IE00B7SZLL34.SGD","LU1623119135.USD","SMMT","SGXZ57979304.SGD","LU0265550946.USD","LU0211331839.USD","LU1430594728.SGD","LU0795875169.SGD","IE000MB6IJN5.SGD","LU2750360641.GBP","LU1934455277.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625910060","title":"Summit Therapeutics Inc : Stifel Initiates Coverage With Buy Rating; Price Target $45","url":"https://stock-news.laohu8.com/highlight/detail?id=2625910060","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625910060?lang=en_us&edition=fundamental","pubTime":"2026-04-08 18:38","pubTimestamp":1775644714,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nFWN40R0TH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SMMT","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625664349","title":"Summit Therapeutics initiated with a Buy at Stifel","url":"https://stock-news.laohu8.com/highlight/detail?id=2625664349","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625664349?lang=en_us&edition=fundamental","pubTime":"2026-04-08 04:23","pubTimestamp":1775593391,"startTime":"0","endTime":"0","summary":"Stifel initiated coverage of Summit Therapeutics (SMMT) with a Buy rating and $45 price target The firm believes the company’s ivonescimab, a “firs...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/summit-therapeutics-initiated-with-a-buy-at-stifel-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/summit-therapeutics-initiated-with-a-buy-at-stifel-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4127","BK4007","BK4211","SMMT","BK4139","LU2488822045.USD","SMMF","BK4539","SF","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624503347","title":"Wells Fargo Reaffirms Their Buy Rating on Summit Therapeutics (SMMT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2624503347","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624503347?lang=en_us&edition=fundamental","pubTime":"2026-04-02 18:57","pubTimestamp":1775127447,"startTime":"0","endTime":"0","summary":"Wells Fargo analyst Mohit Bansal maintained a Buy rating on Summit Therapeutics yesterday and set a price target of $30.00. The company’s shares cl...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wells-fargo-reaffirms-their-buy-rating-on-summit-therapeutics-smmt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wells-fargo-reaffirms-their-buy-rating-on-summit-therapeutics-smmt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SMMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623976391","title":"Barclays Remains a Hold on Summit Therapeutics (SMMT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2623976391","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623976391?lang=en_us&edition=fundamental","pubTime":"2026-03-30 14:57","pubTimestamp":1774853820,"startTime":"0","endTime":"0","summary":"In a report released today, Etzer Darout from Barclays maintained a Hold rating on Summit Therapeutics, with a price target of $18.00. According to...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/barclays-remains-a-hold-on-summit-therapeutics-smmt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/barclays-remains-a-hold-on-summit-therapeutics-smmt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SMMT","LU2488822045.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623533894","title":"Summit Therapeutics Links Ivonescimab Brain Metastases Data To November PDUFA","url":"https://stock-news.laohu8.com/highlight/detail?id=2623533894","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623533894?lang=en_us&edition=fundamental","pubTime":"2026-03-29 02:11","pubTimestamp":1774721461,"startTime":"0","endTime":"0","summary":"Summit Therapeutics presented new Phase III data on ivonescimab at the 2026 European Lung Cancer Congress in EGFR mutated NSCLC.\nThe data highlighted improved intracranial progression free survival, including in patients with brain metastases.\nThe company has submitted a Biologics License Application to the FDA, with a PDUFA decision date set for November.\n\nSummit Therapeutics, trading as NasdaqGM:SMMT, is drawing attention after sharing these late stage results alongside a confirmed FDA...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-smmt/summit-therapeutics/news/summit-therapeutics-links-ivonescimab-brain-metastases-data","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-smmt/summit-therapeutics/news/summit-therapeutics-links-ivonescimab-brain-metastases-data","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","SMMF","BK4211","LENZ","BK4007","LU2488822045.USD","SMMT","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622879571","title":"Summit Therapeutics presents HARMONi intracranial efficacy findings for ivonescimab plus chemotherapy in EGFR-mutated NSCLC; intracranial PFS HR narrows to 0.53 in patients with baseline brain metastases","url":"https://stock-news.laohu8.com/highlight/detail?id=2622879571","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622879571?lang=en_us&edition=fundamental","pubTime":"2026-03-28 00:25","pubTimestamp":1774628756,"startTime":"0","endTime":"0","summary":"Summit Therapeutics presents HARMONi intracranial efficacy findings for ivonescimab plus chemotherapy in EGFR-mutated NSCLC; intracranial PFS HR narrows to 0.53 in patients with baseline brain metastases. Summit Therapeutics published a medical research presentation on intracranial efficacy of ivonescimab plus chemotherapy in EGFR-mutated non-squamous NSCLC after progression on a third-generation EGFR-TKI.The document describes HARMONi as a global, randomized, double-blind phase 3 trial comparing ivonescimab plus pemetrexed and carboplatin with placebo plus the same chemotherapy in 438 patients.In a prespecified exploratory analysis, median intracranial PFS in patients with baseline brain metastases was 10.1 months with ivonescimab plus chemotherapy versus 6.5 months with placebo plus chemotherapy.For patients without baseline brain metastases, median intracranial PFS was 15.7 months with ivonescimab plus chemotherapy versus 11.6 months with placebo plus chemotherapy.Disclaimer: This n","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDL1SQJqt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","BK4139","SMMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622879575","title":"Summit Therapeutics releases HARMONi Phase 3 ivonescimab HRQoL presentation; trial enrollment totals 438 patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2622879575","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622879575?lang=en_us&edition=fundamental","pubTime":"2026-03-28 00:25","pubTimestamp":1774628745,"startTime":"0","endTime":"0","summary":"Summit published a medical research poster on health-related quality of life results from the phase 3 HARMONi trial evaluating ivonescimab plus chemotherapy versus placebo plus chemotherapy in previously treated EGFR-mutant non-squamous NSCLC.The randomized study enrolled 438 patients, split 1:1 between treatment arms.Median time to deterioration in EORTC QLQ-C30 global health status/quality of life was 7.0 months with ivonescimab plus chemotherapy versus 6.5 months with placebo plus chemotherapy.Quality-of-life analyses reported no statistically significant or clinically meaningful differences between arms across EORTC QLQ-C30 subscales through cycle 15.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Summit Therapeutics Inc. published","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDLc45BmD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SMMT","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622829184","title":"Summit Therapeutics to present multiple ivonescimab data sets at ELCC 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2622829184","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622829184?lang=en_us&edition=fundamental","pubTime":"2026-03-27 20:21","pubTimestamp":1774614098,"startTime":"0","endTime":"0","summary":"Summit Therapeutics (SMMT) announced that data for its novel, potential first-in-class investigational bispecific antibody, ivonescimab, will be pr...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/summit-therapeutics-to-present-multiple-ivonescimab-data-sets-at-elcc-2026-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/summit-therapeutics-to-present-multiple-ivonescimab-data-sets-at-elcc-2026-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4211","BK4539","BK4007","SMMF","LENZ","SMMT","BK4139","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622829620","title":"Summit Therapeutics announces ELCC 2026 presentations; intracranial PFS climbs to 10.1 months on ivonescimab plus chemotherapy in HARMONi patients with baseline brain metastases","url":"https://stock-news.laohu8.com/highlight/detail?id=2622829620","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622829620?lang=en_us&edition=fundamental","pubTime":"2026-03-27 20:15","pubTimestamp":1774613716,"startTime":"0","endTime":"0","summary":"Summit Therapeutics announces ELCC 2026 presentations; intracranial PFS climbs to 10.1 months on ivonescimab plus chemotherapy in HARMONi patients with baseline brain metastases. Summit said updated Phase III data on ivonescimab in advanced non-small cell lung cancer will be presented as three posters at the European Lung Cancer Congress 2026 in Copenhagen on March 27, from 1:00 to 2:00 pm CET.One poster from the HARMONi trial  will report intracranial progression-free survival of 10.1 months with ivonescimab plus chemotherapy vs 6.5 months with chemotherapy in patients with baseline brain metastases .In HARMONi patients without baseline CNS metastases, intracranial progression-free survival was 15.7 months with ivonescimab plus chemotherapy vs 11.6 months with chemotherapy .Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informationa","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDL2sc4rM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SMMT","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120636887","title":"UK Vehicle Production Plummets in February Amid Export Weakness","url":"https://stock-news.laohu8.com/highlight/detail?id=1120636887","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120636887?lang=en_us&edition=fundamental","pubTime":"2026-03-27 17:40","pubTimestamp":1774604421,"startTime":"0","endTime":"0","summary":"Data from the UK's Society of Motor Manufacturers and Traders (SMMT) revealed a significant decline in British car production for February, highlighting increasing pressures on the sector. This comes...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SMMT","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620738809","title":"Analysts Are Bullish on Top Healthcare Stocks: Scholar Rock Holding (SRRK), Summit Therapeutics (SMMT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620738809","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620738809?lang=en_us&edition=fundamental","pubTime":"2026-03-20 19:20","pubTimestamp":1774005609,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Scholar Rock Holding (SRRK), Summit Therapeutics (SM...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-scholar-rock-holding-srrk-summit-therapeutics-smmt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-scholar-rock-holding-srrk-summit-therapeutics-smmt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","XBI","LU2488822045.USD","SMMT","BLSG","BLSX","LU0128526141.USD","BK4581","BK4139","BK4588","SRRK","BK4112","LABU","LU0029874061.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619145925","title":"U.S. RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Cogent Biosciences, Summit Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2619145925","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619145925?lang=en_us&edition=fundamental","pubTime":"2026-03-16 18:00","pubTimestamp":1773655210,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Cogent Biosciences, Summit TherapeuticsMarch 16 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-liste","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nL4N4040QY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APEI","AXP","KO","XOM","XOMX","APA","MULL","MUU","ALG","RBRK","CVX","SCM","PFSI","AAL","BC","PI","AR","DSGN","ABVX","KYMR","XOMZ","ADBE","FITB","S","BRBR","BLDR","TALO","PSX","MU","CDRE","CRC","VLO","SMMT","COGT","AXPG","ALNY","INSM","RCL","ADBG","XOMO","AALG","MPC","AROC","RVMD","AA","ECL","INCY","MUD","RPAY"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2616737347","title":"Is Summit Therapeutics (SMMT) Now Pricing In Too Much Hope After Strong Multi Year Gains","url":"https://stock-news.laohu8.com/highlight/detail?id=2616737347","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616737347?lang=en_us&edition=fundamental","pubTime":"2026-03-04 01:41","pubTimestamp":1772559707,"startTime":"0","endTime":"0","summary":"If you are wondering whether Summit Therapeutics is priced attractively or already expensive, you will want to understand how its current share price compares with different measures of underlying value.\nThe stock recently closed at US$16.19, with returns of 0.6% over 7 days, 11.8% over 30 days, a 7.6% decline year to date, a 15.4% decline over 1 year, and a very large gain over 3 years and 189.1% over 5 years. Taken together, these figures point to a mix of past momentum and more recent...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-smmt/summit-therapeutics/news/is-summit-therapeutics-smmt-now-pricing-in-too-much-hope-aft","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-smmt/summit-therapeutics/news/is-summit-therapeutics-smmt-now-pricing-in-too-much-hope-aft","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4211","SMMT","LU2488822045.USD","HOPE","DCF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.smmttx.com","stockEarnings":[{"period":"1week","weight":-0.1221},{"period":"1month","weight":0.2308},{"period":"3month","weight":0.339},{"period":"6month","weight":0.1452},{"period":"1year","weight":-0.3984},{"period":"ytd","weight":0.2624}],"compareEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":0.087},{"period":"3month","weight":0.0359},{"period":"6month","weight":0.0542},{"period":"1year","weight":0.3059},{"period":"ytd","weight":0.047}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":0.093233},{"month":2,"riseRate":0.454545,"avgChangeRate":0.0357},{"month":3,"riseRate":0.454545,"avgChangeRate":0.039344},{"month":4,"riseRate":0.5,"avgChangeRate":0.045322},{"month":5,"riseRate":0.545455,"avgChangeRate":0.099475},{"month":6,"riseRate":0.363636,"avgChangeRate":-0.086722},{"month":7,"riseRate":0.636364,"avgChangeRate":0.088383},{"month":8,"riseRate":0.454545,"avgChangeRate":-0.007003},{"month":9,"riseRate":0.363636,"avgChangeRate":0.075404},{"month":10,"riseRate":0.272727,"avgChangeRate":-0.047867},{"month":11,"riseRate":0.363636,"avgChangeRate":-0.015842},{"month":12,"riseRate":0.454545,"avgChangeRate":0.356783}],"exchange":"NASDAQ","name":"Summit Therapeutics PLC","nameEN":"Summit Therapeutics PLC","securityTypeName":"DR","adrRate":"1:5"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Summit Therapeutics PLC(SMMT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Summit Therapeutics PLC(SMMT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Summit Therapeutics PLC,SMMT,Summit Therapeutics PLC股票,Summit Therapeutics PLC股票老虎,Summit Therapeutics PLC股票老虎国际,Summit Therapeutics PLC行情,Summit Therapeutics PLC股票行情,Summit Therapeutics PLC股价,Summit Therapeutics PLC股市,Summit Therapeutics PLC股票价格,Summit Therapeutics PLC股票交易,Summit Therapeutics PLC股票购买,Summit Therapeutics PLC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Summit Therapeutics PLC(SMMT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Summit Therapeutics PLC(SMMT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction